Skip to main content
To the Editor: Psoriasis is a chronic remitting inflammatory skin disease of unknown etiology. Various medications have been reported to induce or exacerbate psoriasis (1), but to date we believe that fluoxetine is the only selective serotonin reuptake inhibitor (SSRI) to have been reported to do so (2). We report two cases of paroxetine-associated psoriasis.
Mr. A, a 37-year-old man with no history of psoriasis, was diagnosed with hepatitis C and began treatment with thrice-weekly subcutaneous interferon injections and oral ribavirin. Psoriatic plaques developed around the injection areas over his bilateral anterior upper thighs. These were controlled adequately with topical hydrocortisone ointment. He began taking paroxetine, 20 mg/day, for clinical depression.
His preexisting mild psoriasis flared up and spread to his arms, legs, back, chest, hands, and scalp. He required 0.1% mometasone scalp lotion and cream to control the psoriasis. Later he stopped taking paroxetine because of sexual side effects. Within a week, he noted an improvement in the psoriasis that continued to resolve over the ensuing months, with treatment with a variety of topical agents. His depression was subsequently treated with mirtazapine with no recrudescence of the psoriasis.
Ms. B, a 51-year-old woman, was referred for treatment of persistent depression with comorbid kleptomania that was only partially responsive to moclobemide, 600 mg/day. She was taking no other medications. Her medical history included psoriasis, which had pursued a relapsing pattern since she was 3 years old. Her last attack had been several years earlier, and no lesions had been present since.
After a washout period, Ms. B began taking paroxetine, 10 mg/day, for 1 week. The dose was then increased to 20 mg/day. After the first week of paroxetine therapy, she noted a return of psoriatic lesions, which proceeded to worsen over the next 2 weeks to involve the scalp, extensor regions, and chest. The psoriasis required treatment with two courses of psoralen and ultraviolet A light, plus topical therapy. It gradually receded after 2 months.
Ms. B was treated with paroxetine for 5 weeks; her symptoms of depression and kleptomania resolved. Given the potential role of paroxetine in exacerbating her psoriasis, fluvoxamine, 100 mg/day, was substituted; at Ms. B’s 6-month follow-up, there was no recurrence of depression, kleptomania, or psoriasis.
Despite extensive use of SSRIs in clinical practice, there have been very few reports of SSRI-related psoriasis. This is possibly because of underreporting, nonrecognition of the association, or nonassociation of the event. The time scale of these two case studies suggests that paroxetine played a causative role in the exacerbation of these patients’ psoriasis. Given the putative role of paroxetine in exacerbating the psoriatic symptoms, rechallenge with paroxetine was not considered.

References

1.
Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM: Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15(5 part 1):1007-1022
2.
Hemlock C, Rosenthal JS, Winston A: Fluoxetine-induced psoriasis. Ann Pharmacother 1992; 26:211-212

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 2113
PubMed: 12450972

History

Published online: 1 December 2002
Published in print: December 2002

Authors

Affiliations

SALLY FRANCES OSBORNE, M.B., Ch.B., B.Sc.
LEANNE STAFFORD, B.Pharm., M.P.S., M.R.Pharms.
KENNETH GORDON DAVID ORR, M.B.B.S., F.R.A.N.Z.C.P.
Fremantle, Western Australia

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share